Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 361

1.

Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents.

Smith AR, Repka TL, Weigel BJ.

Pediatr Blood Cancer. 2005 Nov;45(6):857-60.

PMID:
15849684
2.

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F; Aprepitant Protocol 054 Study Group.

Cancer. 2003 Jun 15;97(12):3090-8.

4.
5.

Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.

Navari RM.

J Support Oncol. 2003 Jul-Aug;1(2):89-103. Review.

PMID:
15352652
6.

Aprepitant--where do we stand in the control of chemotherapy-induced nausea and vomiting?

Sarcev T, Secen N, Zaric B, Milovancev A.

J BUON. 2008 Jul-Sep;13(3):333-9. Review.

PMID:
18979546
7.

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group.

J Clin Oncol. 2003 Nov 15;21(22):4112-9. Epub 2003 Oct 14.

PMID:
14559886
8.

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.

de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ.

J Clin Oncol. 2003 Nov 15;21(22):4105-11. Epub 2003 Oct 14.

PMID:
14559891
9.

A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.

Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B.

Breast Cancer Res Treat. 2009 Feb;113(3):529-35. doi: 10.1007/s10549-008-9957-9. Epub 2008 Mar 10.

PMID:
18327706
10.
11.

Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.

Massaro AM, Lenz KL.

Ann Pharmacother. 2005 Jan;39(1):77-85. Epub 2004 Nov 23. Review.

PMID:
15562136
12.

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ.

Cancer. 2003 May 1;97(9):2290-300.

13.

Aprepitant: a substance P antagonist for chemotherapy induced nausea and vomiting.

Girish C, Manikandan S.

Indian J Cancer. 2007 Jan-Mar;44(1):25-30. Review.

14.

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ.

Eur J Cancer. 2003 May;39(8):1074-80.

PMID:
12736106
15.

Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.

Navari RM.

Expert Rev Anticancer Ther. 2008 Nov;8(11):1733-42. doi: 10.1586/14737140.8.11.1733. Review.

PMID:
18983233
16.

Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.

Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M.

Support Care Cancer. 2009 May;17(5):589-94. doi: 10.1007/s00520-008-0535-9. Epub 2008 Nov 27.

PMID:
19037667
17.

The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.

Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Wit Rd, Carides AD, Taylor A, Evans JK, Horgan KJ.

Eur J Cancer. 2005 Jun;41(9):1278-85.

PMID:
15939263
18.

Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.

Herrstedt J.

Expert Opin Drug Saf. 2004 May;3(3):231-48. Review.

PMID:
15155151
19.
20.

Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV).

Choi MR, Jiles C, Seibel NL.

J Pediatr Hematol Oncol. 2010 Oct;32(7):e268-71. doi: 10.1097/MPH.0b013e3181e5e1af.

PMID:
20736848
Items per page

Supplemental Content

Write to the Help Desk